Skip to content

Study · Randomized controlled trial · n = 25 · 2009

6 results

A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.

Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I

Hepatology international8 May 2009Cited by 24 (Europe PMC)

PMID19669251 (opens in a new tab)PMCIDPMC2748379 (opens in a new tab)DOI10.1007/s12072-009-9132-3 (opens in a new tab)PepBankPUB-19669251
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with unresectable HCC, TACE plus thymalfasin gave a response rate of 57.1% versus 45.5% with TACE alone, which was not a significant difference (P = 1.0).

    In plain wordsIn adults with liver cancer, adding thymalfasin to TACE did not give a significantly higher response rate than TACE alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeResponse rate (transplant eligibility or no progression through week 72)
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Responders
    57.1%
    TACE + thymalfasin
    Responders
    45.5%
    TACE alone

    Source sentences

    Summary
    Eight of fourteen (57.1%) patients in the TACE + thymalfasin group versus 5 of 11 (45.5%) patients in the TACE-only group became responders (P = 1.0).
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with unresectable HCC, 4 of 14 patients with TACE plus thymalfasin became eligible for transplant versus none of 11 with TACE alone (no test reported).

    In plain wordsIn adults with liver cancer, more patients became eligible for transplant with thymalfasin plus TACE than with TACE alone; no test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseEligibility for transplant
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Four of fourteen TACE + thymalfasin patients versus none of 11 TACE-only patients became eligible for transplant.
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with unresectable HCC, median overall survival was 110.3 weeks with TACE plus thymalfasin versus 57.0 weeks with TACE alone, which was not significant (P = 0.45).

    In plain wordsIn adults with liver cancer, survival was longer on average with thymalfasin plus TACE than TACE alone, but the difference was not significant.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeMedian overall survival
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Mortality · Cancer
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Median overall survival
    110.3 weeks
    TACE + thymalfasin
    Median overall survival
    57 weeks
    TACE alone

    Source sentences

    Summary
    Median overall survival time was 110.3 weeks for the TACE + thymalfasin group versus 57.0 weeks for the TACE-only group (P = 0.45).
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with unresectable HCC, seven patients in each group experienced serious adverse events.

    In plain wordsIn adults with liver cancer, the same number of patients had serious side effects with thymalfasin plus TACE as with TACE alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSerious adverse events
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Seven patients in each group experienced serious adverse events
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with unresectable HCC, there were no bacterial infections with TACE plus thymalfasin versus 4 with TACE alone (no test reported).

    In plain wordsIn adults with liver cancer, fewer bacterial infections occurred with thymalfasin plus TACE than with TACE alone; no test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBacterial infections
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Adverse events · Infection
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    there were no bacterial infections in the TACE + thymalfasin group versus 4 in the TACE-only group.
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with unresectable HCC, 3 deaths occurred with TACE plus thymalfasin and 5 with TACE alone (no test reported).

    In plain wordsIn adults with liver cancer, there were fewer deaths with thymalfasin plus TACE than with TACE alone; no test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDeaths
    Study

    n = 25

    Comparator
    TACE alone
    Outcome group
    Mortality · Cancer
    Studied dose
    1.6 mg, 5 times weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were 3 deaths in the TACE + thymalfasin group and 5 in the TACE-only group.
    1 context sentence
    Summary · context
    In this phase II, randomized trial, 25 patients received either TACE plus thymalfasin (1.6 mg SC, 5 times weekly; n = 14) or TACE alone (n = 11) for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.